BioLineRx Company Insiders
| BLRX Stock | USD 0.27 0.01 3.57% |
BioLineRx employs about 79 people. The company is managed by 12 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 6.58 employees per reported executive. Break down of BioLineRx's management performance can provide insight into the company performance.
| Ella Sorani President Vice President-Development |
BioLineRx |
BioLineRx Management Team Effectiveness
The company has return on total asset (ROA) of (0.3523) % which means that it has lost $0.3523 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7194) %, meaning that it created substantial loss on money invested by shareholders. BioLineRx's management efficiency ratios could be used to measure how well BioLineRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.3 in 2024. Return On Capital Employed is likely to rise to -1.43 in 2024. Debt To Assets is likely to rise to 0.16 in 2024, whereas Total Assets are likely to drop slightly above 53.7 M in 2024.Common Stock Shares Outstanding is likely to rise to about 67.4 M in 2024, whereas Net Loss is likely to drop (25.6 M) in 2024.
BioLineRx Workforce Comparison
BioLineRx is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,312. BioLineRx holds roughly 79.0 in number of employees claiming about 2.39% of equities under Health Care industry.
BioLineRx Profit Margins
The company has Profit Margin (PM) of (1.77) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.07.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.25 | 0.27 |
|
|
BioLineRx Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. BioLineRx Price Series Summation is a cross summation of BioLineRx price series and its benchmark/peer.
BioLineRx Notable Stakeholders
A BioLineRx stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioLineRx often face trade-offs trying to please all of them. BioLineRx's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioLineRx's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ella Sorani | Vice President-Development | Profile | |
| Holly MBA | President USA | Profile | |
| CPA CPA | Chief Officer | Profile | |
| Raziel Fried | Treasurer Director | Profile | |
| Adam Esq | General Compliance | Profile | |
| Jael MSc | QA RA | Profile | |
| CPA MBA | Chief Officer | Profile | |
| Advocate Kotler | Gen Officer | Profile | |
| Liron MBA | Director Devel | Profile | |
| John Lacey | Head Relations | Profile | |
| Abi MD | Chief Officer | Profile | |
| LLB BSc | Head Advisor | Profile |
About BioLineRx Management Performance
The success or failure of an entity such as BioLineRx often depends on how effective the management is. BioLineRx management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioLineRx management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioLineRx management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.24) | (1.30) | |
| Return On Capital Employed | (1.50) | (1.43) | |
| Return On Assets | (0.95) | (0.90) | |
| Return On Equity | (4.58) | (4.35) |
Please note, the imprecision that can be found in BioLineRx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioLineRx. Check BioLineRx's Beneish M Score to see the likelihood of BioLineRx's management manipulating its earnings.
BioLineRx Workforce Analysis
Traditionally, organizations such as BioLineRx use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioLineRx within its industry.BioLineRx Manpower Efficiency
Return on BioLineRx Manpower
| Revenue Per Employee | 60.8K | |
| Revenue Per Executive | 400K | |
| Net Loss Per Employee | 767.3K | |
| Net Loss Per Executive | 5.1M | |
| Working Capital Per Employee | 206.7K | |
| Working Capital Per Executive | 1.4M |
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.